AbbVie Inc (ABBV)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+25% over the past year+3
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 10% y/y+5
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product news, driven by the positive Phase 3 INTREPID results for lutikizumab in hidradenitis suppurativa. Continuation likelihood over the next few weeks is moderate (~50-60%), since single-trial readouts often hold initial gains but require confirmatory data and regulatory steps to sustain momentum. Informational only — not financial advice.
- Jim Cramer and Ken Fisher Like This Healthcare StockYahoo · 2026-10-22
- JNJ Stock Has a New Growth Story, but One Business Needs to Catch UpYahoo · 2026-10-22
- AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis SuppurativaYahoo · 2026-10-22
- Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy LiftingChartMill · 2026-10-22
- Was There Any Sign Merck Stock Would Run?Yahoo · 2026-10-22
Any AI summary is an interpretation of public news, not advice or a price target.